Cross-Sector entity
Churchill Downs Incorporated is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. The tracked stories average 3 original sources each.
3 verified stories tracked
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Churchill Downs Incorporated is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. The tracked stories average 3 original sources each. Schrödinger appears in 3 tracked Cross-Sector stories from February 26, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Schrödinger. Shared-story counts are live from our verified record — not editorial picks.
Schrödinger and GoodRx reported full-year 2025 results, demonstrating the growing financial impact of AI-driven computational platforms in drug discovery and healthcare. These reports, alongside Churchill Downs' record performance, highlight a broader trend of data-centric companies leveraging machine learning to optimize specialized market verticals.
GoodRx and Schrödinger released their full-year 2025 financial results, highlighting a critical period of transition for digital health and computational drug discovery. While GoodRx focused on stabilizing its prescription marketplace margins, Schrödinger demonstrated the growing scalability of its AI-driven software platform alongside its internal clinical pipeline.
GoodRx reported Q4 2025 sales that exceeded market expectations, yet shares fell nearly 12% as investors weighed future guidance and margin pressures. Meanwhile, Schrödinger is pivoting toward a hosted platform model, targeting 10-15% growth in annual contract value for its computational drug discovery suite.
Source: markets.businessinsider.com · pharmiweb.com
